RDTCF (Rapid Dose Therapeutics) Debt-to-Asset : 1.56 (As of Nov. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Rapid Dose Therapeutics Debt-to-Asset?

Rapid Dose Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Nov. 2024 was $0.00 Mil. Rapid Dose Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Nov. 2024 was $1.87 Mil. Rapid Dose Therapeutics's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Nov. 2024 was $1.20 Mil. Rapid Dose Therapeutics's debt to asset for the quarter that ended in Nov. 2024 was 1.56.

Rapid Dose Therapeutics Debt-to-Asset Historical Data

The historical data trend for Rapid Dose Therapeutics's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rapid Dose Therapeutics Debt-to-Asset Chart

Rapid Dose Therapeutics Annual Data

Trend

Sep15

Sep16

Sep17

Sep18

Feb19

Feb20

Feb21

Feb22

Feb23

Feb24

Debt-to-Asset

Get a 7-Day Free Trial

0.29

0.54

0.38

0.72

1.19

Rapid Dose Therapeutics Quarterly Data
	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24	May24	Aug24	Nov24
Debt-to-Asset	Get a 7-Day Free Trial															1.38	1.19	1.42	1.52	1.56

Competitive Comparison of Rapid Dose Therapeutics's Debt-to-Asset

For the Biotechnology subindustry, Rapid Dose Therapeutics's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Rapid Dose Therapeutics's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rapid Dose Therapeutics's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Rapid Dose Therapeutics's Debt-to-Asset falls into.

Save Embed

;

Save Embed

;

Rapid Dose Therapeutics Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Rapid Dose Therapeutics's Debt-to-Asset for the fiscal year that ended in Feb. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.091	+	1.574)	/	1.396
	=	1.19

Rapid Dose Therapeutics's Debt-to-Asset for the quarter that ended in Nov. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	1.868)	/	1.195
	=	1.56

Rapid Dose Therapeutics (OTCPK:RDTCF) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Rapid Dose Therapeutics Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Rapid Dose Therapeutics's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Rapid Dose Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rapid Dose Therapeutics Corp (OTCPK:RDTCF) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

DOSE:Canada

Address

1121 Walkers Line, Unit 3, Burlington, ON, CAN, L7N 2G4

Website

https://www.rapid-dose.com

Rapid Dose Therapeutics Corp is a Canadian biotechnology company revolutionizing drug delivery through innovation. The company's flagship product QuickStrip is a thin, orally dissolvable film, that can be infused with an infinite list of active ingredients (nutraceuticals, pharmaceuticals, vaccines, and cannabis) that are delivered quickly into the bloodstream resulting in rapid onset of the active ingredient.